Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPFFR1 | Q9GZQ6 | 6/20 | 0.52 |
| ▸ | NPFFR2 | Q9Y5X5 | 6/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 7/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23268296 | 0.93 | NPFFR1 (0.56) | NPFFR1NPFFR2CYP2D6ALDH1A1KMT2A | |
| SCHEMBL8572168 | 0.90 | NPFFR1 (0.51) | NPFFR1NPFFR2CYP2D6ALDH1A1KMT2A | |
| SCHEMBL1031172 | 0.84 | NPFFR1 (0.53) | NPFFR1NPFFR2CYP2D6ALDH1A1KMT2A | |
| SCHEMBL23120819 | 0.83 | NPFFR1 (0.53) | NPFFR1NPFFR2CYP2D6ALDH1A1KMT2A | |
| SCHEMBL22961966 | 0.83 | NPFFR1 (0.53) | NPFFR1NPFFR2CYP2D6ALDH1A1KMT2A | |
| SCHEMBL28249793 | 0.83 | NPFFR1 (0.53) | NPFFR1NPFFR2CYP2D6ALDH1A1KMT2A | |
| SCHEMBL13738215 | 0.82 | NPFFR1 (0.57) | NPFFR1NPFFR2CYP2D6ALDH1A1KMT2A | |
| SCHEMBL4295050 | 0.82 | NPFFR1 (0.57) | NPFFR1NPFFR2CYP2D6ALDH1A1KMT2A | |
| SCHEMBL1770778 | 0.82 | NPFFR1 (0.57) | NPFFR1NPFFR2CYP2D6ALDH1A1KMT2A | |
| SCHEMBL4795708 | 0.82 | NPFFR1 (0.57) | NPFFR1NPFFR2CYP2D6ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026085629-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF | Université de Montréal (CA) | 2026-04-30 | — | — | WO | disclosed |
| US-11597733-B2 | Compounds and compositions for the treatment of parasitic diseases | NOVARTIS AG (CH) | 2023-03-07 | — | — | US | disclosed |
| WO-2021078120-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | NOVARTIS AG (CH) | 2021-04-29 | — | — | WO | disclosed |
| US-20210115065-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | NOVARTIS AG (CH) | 2021-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11597733-B2 | Compounds and compositions for the treatment of parasitic diseases | ABCB11, SQLE, FURIN | NPFFR1 3942/4885NPFFR2 4268/4885CYP2D6 285/4885 |
| US-20210115065-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | ABCB11, SQLE, FURIN | NPFFR1 3942/4885NPFFR2 4268/4885CYP2D6 285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.